Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Siga Technologies Inc. SIGA

Healthcare — Drug Manufacturers Specialty & Generic
Dividend Champion (3y)
Growth Flags show if company had growth for consecutive years

Siga Technologies Inc. (SIGA) Business Profile

Company Overview

SIGA Technologies Inc. (SIGA) is a leading pharmaceutical company specializing in the development and commercialization of solutions for addressing unmet medical needs in the areas of infectious diseases and biodefense. Founded in 1995, SIGA is headquartered in New York City, USA. The company has established itself as a key player in the biodefense sector, particularly in the development of countermeasures against biological threats. SIGA’s leadership team includes experienced professionals with deep expertise in pharmaceuticals, biotechnology, and public health. Key executives include Dr. Phillip L. Gomez, who serves as the Chief Executive Officer, and Daniel J. Luckshire, the Chief Financial Officer. Their strategic vision has been instrumental in driving SIGA’s growth and innovation.

Core Business Segments

SIGA operates primarily in the biodefense and infectious disease sectors. Its core business segments include:

1. Biodefense Pharmaceuticals

SIGA’s flagship product, TPOXX® (tecovirimat), is the first antiviral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox. TPOXX® is a cornerstone of SIGA’s biodefense portfolio and is also approved in Canada and Europe for similar indications. The product is stockpiled by governments worldwide as part of their preparedness strategies against potential bioterrorism threats.

2. Antiviral Research and Development

SIGA invests heavily in research and development (R&D) to expand its portfolio of antiviral treatments. The company is actively exploring treatments for other orthopoxvirus infections, such as monkeypox and cowpox, as well as other infectious diseases that pose significant public health risks.

3. Government Contracts and Partnerships

SIGA collaborates closely with government agencies, including the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA). These partnerships are critical for funding R&D initiatives and ensuring the availability of TPOXX® in national stockpiles.

Business Model

SIGA’s business model is centered on the development, manufacturing, and distribution of antiviral treatments, primarily for government stockpiling programs. The company generates revenue through:

  • Government Contracts: SIGA secures long-term contracts with governments for the procurement of TPOXX® and other medical countermeasures.
  • Licensing Agreements: The company licenses its technologies to international partners to expand its global reach.
  • Research Grants: SIGA receives funding from government agencies and other organizations to support its R&D efforts.

This model ensures a steady revenue stream while enabling SIGA to invest in innovative solutions for emerging infectious diseases.

Strategic Direction

SIGA is focused on several strategic priorities to drive future growth:

  • Expansion of Product Portfolio: The company aims to develop new antiviral treatments for a broader range of infectious diseases, including emerging viral threats.
  • Global Market Penetration: SIGA is working to expand its presence in international markets by securing regulatory approvals and establishing partnerships with foreign governments.
  • Sustainability Goals: SIGA is committed to sustainable practices in its operations, including reducing its environmental footprint and ensuring ethical sourcing of raw materials.
  • Innovation in R&D: The company plans to leverage advanced technologies, such as artificial intelligence and genomics, to accelerate drug discovery and development.

Competitive Landscape

SIGA operates in a niche market with limited direct competition. However, it faces competition from companies involved in antiviral drug development and biodefense. Key competitors include:

  • Emergent BioSolutions Inc.: A leader in biodefense and public health preparedness, offering vaccines and therapeutics for biological threats.
  • Chimerix Inc.: Focused on developing antiviral treatments, including those for smallpox and other orthopoxvirus infections.
  • Tonix Pharmaceuticals: Engaged in the development of therapies for infectious diseases and biodefense applications.

Despite the competition, SIGA’s first-mover advantage with TPOXX® and its strong government partnerships provide a significant competitive edge.

Risk Factors

While SIGA has a strong market position, it faces several risks:

  • Market Dependence: The company relies heavily on government contracts for revenue, making it vulnerable to changes in government funding priorities.
  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals for new products could impact SIGA’s growth.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes SIGA to potential disruptions in the production and distribution of its products.
  • Emerging Competition: Advances by competitors in antiviral drug development could erode SIGA’s market share.

Recent Developments

SIGA has made significant strides in recent years:

  • Monkeypox Response: In response to the global monkeypox outbreak, SIGA has ramped up production and distribution of TPOXX® to affected regions.
  • International Approvals: The company secured regulatory approvals for TPOXX® in Europe and Canada, expanding its global footprint.
  • R&D Milestones: SIGA has initiated clinical trials for new antiviral candidates targeting other orthopoxviruses and emerging infectious diseases.
  • Corporate Strategy: The company has strengthened its partnerships with international organizations to enhance global health security.

Investment Considerations

Strengths:

  • Market leader in biodefense pharmaceuticals with a proven product (TPOXX®).
  • Strong government partnerships and long-term contracts.
  • Robust R&D pipeline with potential for new product launches.
  • Expanding global presence through international approvals and partnerships.

Risks:

  • Heavy reliance on government contracts for revenue.
  • Exposure to regulatory and supply chain risks.
  • Limited diversification beyond biodefense and infectious diseases.

Conclusion

SIGA Technologies Inc. is a pioneering company in the biodefense and infectious disease sectors. With its flagship product, TPOXX®, and a robust R&D pipeline, SIGA is well-positioned to address global health challenges. While the company faces risks related to market dependence and regulatory hurdles, its strong government partnerships and strategic initiatives provide a solid foundation for future growth. As the world continues to prioritize pandemic preparedness and biodefense, SIGA is poised to play a critical role in safeguarding public health.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us